title: [Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial].
abstract: A group of 25 patients with uncomplicated BPH was treated mepartricin 150,000 U (40 mg) once in the evening for 60 days and the results were compared with those obtained in 25 patients treated with mepartricin 50,000 U (13 mg) t.d.s. Efficacy and tolerance of both treatment schemes were good. In the group treated with on single dose at night some symptoms such as nocturia and pollakiuria regressed more rapidly.
authors.affiliation: Clinica Urologica, Napoli.
authors.forename: V
authors.initials: V
authors.lastname: Mirone
authors.forename: D
authors.initials: D
authors.lastname: Prezioso
authors.forename: A
authors.initials: A
authors.lastname: Palmieri
authors.forename: T
authors.initials: T
authors.lastname: Lotti
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008613:Mepartricin / Q000008:administration & dosage*; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D008613:Mepartricin
vernacular_title: Mepartricina 150.000 U (40 mg) vs mepartricina 50.000 U (13 mg) nel trattamento della IPB. Ricerca clinica in doppio cieco.